Nonalcoholic Steatohepatitis (NASH), now also known as Metabolic Dysfunction-Associated Steatohepatitis (MASH), is a serious liver condition that occurs when fat builds up in the liver and leads to inflammation and liver cell damage. While many people with fatty liver disease may not show symptoms, NASH/MASH can silently progress and result in liver fibrosis, cirrhosis, or even liver failure. It’s most common in individuals with obesity, Type 2 diabetes, or metabolic syndrome, and as these health conditions rise globally, so does the prevalence of NASH/MASH.
An upcoming clinical trial in New Bedford, MA will explore a potential treatment for individuals with NASH/MASH. Eligible participants will be closely monitored by healthcare professionals and contribute to research that may shape new approaches to treating fatty liver disease.
